Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.
Active, not recruiting · NCT05788081 · Registry updated 2025-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2025-08-20 | NCT05788081 |
7 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Austin Health | 17 |
| Barwon Health | 4 |
| Bristol-Myers Squibb | 422 |
| Eastern Health | 8 |
| Fiona Stanley Hospital | 5 |
| Grampians Health | 1 |
| Olivia Newton-John Cancer Research Institute | 8 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Austin Health | Heidelberg | Australia | 2 |
| Eastern Health | Box Hill | Australia | 15 |
| Fiona Stanley Hospital | Perth | Australia | 5 |
| Grampians Health | Ballarat | Australia | 2 |
| University Hospital Geelong, Barwon Health | Geelong | Australia | 1 |